First-Year Funding of Early Detection Research Network Complete

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 7
Volume 9
Issue 7

BETHESDA, Md-The National Cancer Institute-sponsored Early Detection Research Network has issued 13 grants totaling $18 million to complete its first year of funding. Last fall, NCI awarded $8 million to set up the network’s initial operations-18 biomarker development laboratories. The new grants will finance the establishment of the program’s other three components: clinical and epidemiologic centers, biomarker validation laboratories, and a data management and coordinating center.

BETHESDA, Md—The National Cancer Institute-sponsored Early Detection Research Network has issued 13 grants totaling $18 million to complete its first year of funding. Last fall, NCI awarded $8 million to set up the network’s initial operations—18 biomarker development laboratories. The new grants will finance the establishment of the program’s other three components: clinical and epidemiologic centers, biomarker validation laboratories, and a data management and coordinating center.

The aim of the network is to unite dozens of research institutions in efforts to search for and evaluate new ways to test for early cancer and for cancer risk.

“Advances in cancer genetics, protein analysis, and other fields offer potential new biomarkers that one day may reduce the burden of cancer,” said Sudhir Srivastava, PhD, MPH, chief of the cancer biomarkers research group in NCI’s Division of Cancer Prevention. “But before they can move from the lab to the clinic, these biomarkers need to be tested systematically. Pooling resources and expertise is vital to this kind of validation.”

The new grants will finance:

Nine clinical and epidemiologic centers that will provide the network with blood, tissue, and other biological samples, as well as medical information on families with a history of cancer, for use in a large-scale evaluation of cancer biomarkers.

Three biomarker validation laboratories, which will standardize biomarker tests, assure their reproducibility, and ready the best tests for clinical trials.

A data management and coordination center to develop standards for data reporting and research new statistical methods for analyzing biomarkers.

Related Videos
A panel of 4 experts on multiple myeloma
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content